Socioeconomic differences persist in use of permanent vs long-acting reversible contraception: An analysis of the National Survey of Family Growth, 2006 to 2010 vs 2015 to 2017.

Implant Intrauterine device Long-acting reversible contraception National Survey of Family Growth Permanent contraception Sociodemographics Tubal ligation

Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
04 2021
Historique:
received: 14 09 2020
revised: 14 12 2020
accepted: 17 12 2020
pubmed: 29 12 2020
medline: 16 10 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Permanent contraception has historically been more prevalent among non-White women with lower education and income. Given increasing popularity of long-acting reversible contraception (LARC), we examine changing sociodemographic patterns of permanent contraception and LARC. We performed a descriptive analysis of the National Survey of Family Growth (NSFG) from 2006 to 2017, with multivariable analyses of the 2006 to 2010 and 2015 to 2017 cohorts. Using multinomial logistic regression, we investigate predictors of contraceptive category (permanent contraception vs LARC, lower-efficacy contraception vs LARC) in reproductive-aged women. Total 8161 respondents were included in 2 distinct but analogous regression analyses: (1) the most recent survey cohort, 2015 to 2017 and (2) the cohort a decade prior, 2006 to 2010. Over this period, the prevalence of LARC increased nearly 3-fold (6.2%-16.7%), while permanent contraception use trended downwards (22%-18.6%). Yet, in adjusted models, we observed little change in the sociodemographic predictors of permanent contraception: from the early to recent cohort, use of permanent contraception (vs LARC) remained less likely among college graduates (multinomial odds ratio (OR) 0.45 [95% confidence interval 0.21, 0.97]) and Hispanic women (OR 0.41 [0.21, 0.82]). In addition, high income (>$74,999) and metropolitan residence came to predict less use (OR 0.33 [0.13, 0.84] and 0.47 [0.23, 0.97]). Multiparity, advanced age (over ≥35), and marital status remained strong predictors of permanent contraception. Although use of LARC nearly equals that of permanent contraception in the most recent NSFG survey, socioeconomic differences persist. Continued effort is needed to detect and address structural barriers to accessing the most effective forms of contraception for women. Comparing 2006-2010 to 2015-2017, reliance on female permanent contraception decreased while LARC use increased, making prevalence more similar. However, significant socioeconomic differences persist in who chooses permanent contraception, with urban, educated, higher income women more likely to use LARC. Ongoing efforts are needed to understand and reduce economic barriers to LARC.

Identifiants

pubmed: 33359509
pii: S0010-7824(20)30461-3
doi: 10.1016/j.contraception.2020.12.008
pii:
doi:

Substances chimiques

Contraceptive Agents, Female 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-254

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Isabel Beshar (I)

Stanford School of Medicine, Stanford University, Stanford, CA, United States. Electronic address: ibeshar@stanford.edu.

Jodi So (J)

Stanford School of Medicine, Stanford University, Stanford, CA, United States.

Meena Chelvakumar (M)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, United States.

Erica P Cahill (EP)

Division of Family Planning Services & Research, Department of Obstetrics & Gynecology, Stanford University, Stanford, CA, United States.

Kate A Shaw (KA)

Division of Family Planning Services & Research, Department of Obstetrics & Gynecology, Stanford University, Stanford, CA, United States.

Jonathan G Shaw (JG)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH